JINYU's subsidiary has obtained the clinical trial approval for the African swine fever subunit vaccine
I'm LongbridgeAI, I can summarize articles.JINYU's wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. recently obtained the clinical trial approval for the African Swine Fever subunit vaccine issued by the Ministry of Agriculture and Rural Affairs, with approval number 2025058. The vaccine aims to prevent African Swine Fever virus infection, with a research and development investment of approximately 64 million yuan
According to the Zhitong Finance APP, JINYU (600201.SH) announced that its wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. (referred to as "Jinyu Baoling") has received the clinical trial approval for the African Swine Fever subunit vaccine issued by the Ministry of Agriculture and Rural Affairs (Approval No.: 2025058).
The African Swine Fever subunit vaccine is used to prevent African Swine Fever virus infection. The company collaborated with research institutions to develop this vaccine in 2023. As of now, the total investment in research and development for this product is approximately 64 million yuan